Accurate lists of current clinical trials are maintained by a number of national authorities. The information is intended for people looking for trials to participate in. However, it may also be useful for those interested in the research that is currently underway.
The databases listed below provide information on current clinical trials (Project title, Description of project, Location, Start date, End date). It is worth searching more than one of these databases as none appear comprehensive:
We have an ongoing list of updates to trials and new trials here:
-
A Study to Investigate the Safety, Tolerability and Pharmacokinetics of Single and Repeat Doses of PC94522 March 2016
Condition: Aspergillosis
Interventions: Drug: PC945 – single doses; Drug: Placebo – single doses; Drug: PC945 – repeat doses; Drug: Placebo – repeat doses
Sponsor: Pulmocide Ltd
Completed -
Evaluation of the Potential for Cytochrome P450 3A4 Inhibition by F901318 Using Oral Midazolam as a Probe12 February 2016
Condition: Invasive Aspergillosis
Intervention: Drug: Midazolam with F901318
Sponsors: F2G Ltd.; Hammersmith Medicines Research
Completed -
Post Marketing Study to Evaluate the Safety and Efficacy of Micafungin Against Fungal Infections Caused by Candida Spp or Aspergillus Spp6 January 2016
Conditions: Aspergillosis; Candidiasis
Intervention: Drug: Micafungin
Sponsor: Astellas Pharma China, Inc.
Terminated -
Post Marketing Study to Evaluate the Efficacy and Safety of Micafungin Treatment on Invasive Aspergillosis6 January 2016
Condition: Invasive Aspergillosis
Intervention: Drug: Micafungin
Sponsor: Astellas Pharma China, Inc.
Terminated -
A Randomized Trial of Itraconazole in Acute Stages of Allergic Bronchopulmonary Aspergillosis12 May 2015
Condition: Allergic Bronchopulmonary Aspergillosis
Interventions: Drug: Itraconazole; Drug: Glucocorticoids
Sponsor: Postgraduate Institute of Medical Education and Research
Recruiting -
Concentrations of Voriconazole in Blood and BAL-fluid After Inhalation and Oral Administration24 March 2015
Condition: Invasive Aspergillosis
Intervention: Drug: Voriconazole
Sponsors: University of Aarhus; Aarhus University Hospital
Terminated -
Single Ascending Oral Dose Study of F90131820 March 2015
Condition: Invasive Aspergillosis
Interventions: Drug: F901318 safety; Drug: F901318 tolerability; Drug: F901318 pharmacokinetics; Other: Placebo safety; Other: Placebo tolerability; Other: Placebo pharmacokinetics
Sponsors: F2G Ltd.; Simbec-Orion Research
Completed -
F901318 Multiple Ascending Dose Study21 January 2015
Condition: Invasive Aspergillosis
Interventions: Drug: F901318; Drug: Placebo
Sponsors: F2G Ltd.; Hammersmith Medicines Research
Completed -
Evaluation of a Therapeutic Strategy Including Nebulised Liposomal Amphotericin B (Ambisome®) in Maintenance Treatment of Allergic Bronchopulmonary Aspergillosis (Cystic Fibrosis Excluded).24 October 2014
Condition: Allergic Bronchopulmonary Aspergillosis
Interventions: Drug: Liposomal amphotericin B (Ambisome®); Drug: placebo
Sponsor: Poitiers University Hospital
Active, not recruiting -
Voriconazole for IPA in Chinese Patients With COPD9 September 2014
Conditions: Invasive Pulmonary Aspergillosis; COPD
Intervention: Drug: Voriconazole
Sponsors: Red Cross Hospital, Hangzhou, China; Sir Run Run Shaw Hospital; Zhejiang Provincial People’s Hospital; First People’s Hospital of Hangzhou; Second People’s Hospital of Hangzhou; Hangzhou Hospital of Traditional Chinese Medicine; Ningbo People’s Hospital; Xiaoshan People’s Hospital; Xiaoshan Hospital; First People’s Hospital Affiliated to Huzhou University
Unknown status